Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosisNew drug toxicities in the onco-nephrology world
Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney International 2015, 87: 909-917. PMID: 25671763, DOI: 10.1038/ki.2015.30.Peer-Reviewed Original ResearchConceptsKidney injuryAnticancer medicationsAdverse renal consequencesAcute kidney injuryChronic kidney diseaseLevel of proteinuriaMore effective therapiesRenal consequencesElectrolyte disturbancesKidney diseaseNephrotoxic effectsNephrotoxic potentialRisk factorsEffective therapyNephrotoxic manifestationsDrug toxicityNew agentsOld drugsNephrology communityResistant cancersClinical arenaAvailable evidenceMedicationsPatientsInjury